ANIK
Anika Therapeutics, Inc.
$15.25
-0.57 (-3.60%)
At close · Jul 17
Market Cap
$202.91M
Shares
13,305,624
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$112.82M
-5.9%
FY2025
Net Income
-$10.88M
+80.7%
FY2025
Gross Margin
56.56%
-6.8pp
FY2025
Operating Margin
-9.8%
-5.6pp
FY2025
Diluted EPS
-$0.76
+80.2%
FY2025
Operating Cash Flow
$11.19M
+107.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $114M – $122.5M | $116.26M | $112.82M | $119.91M | $166.66M | $156.24M | $147.79M | $130.46M | $114.61M | $105.56M | $113.42M | $103.38M | $93M | $105.59M | $75.08M | $71.36M | $64.78M | |
| — | $48.14M | $49.01M | $43.91M | $63.57M | $62.66M | $64.85M | $61.43M | $28.75M | $31.28M | $27.36M | $24.03M | $21.05M | $20.93M | $22.77M | $28.99M | $26.78M | |
| — | $68.12M | $63.81M | $76M | $103.09M | $93.58M | $82.94M | $69.03M | $21.12M | $19.95M | $20.17M | $20.76M | $19.32M | $12.37M | $13.95M | $14.19M | — | |
| — | — | 56.56% | 63.38% | 61.85% | 59.89% | 56.12% | 52.91% | 18.43% | 18.9% | 17.78% | 20.08% | 20.77% | 11.71% | 18.58% | 19.88% | — | |
| — | $26.42M | $25.77M | $25.54M | $32.69M | $28.18M | $27.33M | $23.43M | $16.67M | $18.19M | $18.79M | $10.73M | $8.99M | $8.14M | $7.06M | $5.39M | $6.17M | |
| — | $53.95M | $49.09M | $55.56M | $95.85M | $84.79M | $74.1M | $60.06M | $34.95M | $34.34M | $21.54M | $18.01M | $14.83M | $15.07M | $12.94M | $14.73M | $17.86M | |
| — | — | $400K | $700K | $7.8M | $7.8M | $7.8M | $7.4M | $1M | $1M | $1M | $1.1M | $1.1M | $2.09M | $2.09M | — | — | |
| — | — | $5.37M | $6.88M | $6.43M | $6.7M | $6.48M | $13.46M | $5.99M | $5.91M | $4.29M | $3.73M | $3.78M | $4.71M | $4.77M | $4.53M | $4M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -$286.84K | -$286.84K | $2.54M | — | |
| — | $80.38M | $74.86M | $81.1M | $190.73M | $112.98M | $80.33M | $97.35M | $80.36M | $83.81M | $67.69M | $52.77M | $44.87M | $44.15M | $42.47M | $51.64M | $50.81M | |
| — | -$12.26M | -$11.05M | -$5.1M | -$87.64M | -$19.4M | $2.62M | -$28.32M | $34.25M | $21.75M | $45.73M | $50.61M | $48.13M | $61.45M | $32.61M | $19.72M | $13.97M | |
| — | — | -9.8% | -4.25% | -52.58% | -12.42% | 1.77% | -21.71% | 29.88% | 20.6% | 40.32% | 48.95% | 51.76% | 58.19% | 43.43% | 27.63% | 21.56% | |
| — | — | -$5.68M | $1.78M | -$81.21M | -$12.7M | $9.1M | -$14.86M | $40.24M | $27.66M | $50.02M | $54.34M | $51.91M | $66.15M | $37.38M | $24.24M | $17.97M | |
| — | — | — | — | — | — | — | -$13K | $25K | $371K | — | — | — | — | — | — | — | |
| — | -$10.26M | -$9.31M | -$2.76M | -$85.33M | -$18.75M | $2.43M | -$28.62M | $36.12M | $23.21M | $46.2M | $50.87M | $48.25M | $61.51M | $32.48M | $19.53M | $13.79M | |
| — | $818K | $672K | $6.06M | -$2.66M | -$3.89M | -$1.71M | -$4.64M | $8.93M | $4.49M | $14.39M | $18.32M | $17.5M | $23.19M | $11.91M | $7.77M | $5.32M | |
| — | -$11.06M | -$10.88M | -$56.39M | -$82.67M | -$14.86M | $4.13M | -$23.98M | $27.19M | $18.72M | $31.82M | $32.55M | $30.76M | $38.32M | $20.57M | $11.76M | $8.47M | |
| — | — | -9.64% | -47.02% | -49.6% | -9.51% | 2.8% | -18.38% | 23.73% | 17.74% | 28.05% | 31.48% | 33.07% | 36.29% | 27.4% | 16.48% | 13.07% | |
| — | -$10.27M | -$9.06M | -$57.23M | -$82.17M | -$15.58M | $2.96M | -$22.63M | $26.82M | $17.98M | $34.35M | $31.88M | $28.6M | $35.52M | $21.53M | $12.17M | $7.95M | |
| USD/shares | — | — | -$0.76 | -$3.83 | -$5.64 | -$1.02 | $0.29 | -$1.69 | $1.93 | $1.30 | $2.18 | $2.22 | $2.06 | $2.61 | $1.46 | $0.89 | $0.65 |
| USD/shares | — | — | -$0.76 | -$3.83 | -$5.64 | -$1.02 | $0.28 | -$1.69 | $1.89 | $1.27 | $2.11 | $2.15 | $2.01 | $2.51 | $1.39 | $0.82 | $0.62 |
| shares | — | — | 14.34M | 14.72M | 14.66M | 14.56M | 14.4M | 14.22M | 14.12M | 14.44M | 14.58M | 14.68M | 14.93M | 14.68M | 14.09M | 13.26M | 13.06M |
| shares | — | — | 14.34M | 14.72M | 14.66M | 14.56M | 14.63M | 14.22M | 14.37M | 14.69M | 15.07M | 15.12M | 15.32M | 15.27M | 14.83M | 14.34M | 13.75M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2025: $135.4M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 2.25×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 34.87×
P/E (TTM)
—
Drug Manufacturers - Specialty & Generic median 20.52×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $70,058,000 | $82,446,000 | $86,911,000 | $83,746,000 | $113,833,000 | $103,182,000 | $90,302,000 | $85,351,000 |
| Europe | $22,214,000 | $19,403,000 | $17,313,000 | $17,227,000 | $19,580,000 | $14,179,000 | $14,744,000 | $11,730,000 |
| Other Location | $20,547,000 | $18,058,000 | $16,568,000 | $12,854,000 | $14,381,000 | $13,096,000 | $9,564,000 | $8,474,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| OEM Channel | $64,406,000 | $77,770,000 | $84,645,000 | $81,675,000 | — | — | — | — |
| Commercial Channel | $48,413,000 | $42,137,000 | $36,147,000 | $32,152,000 | — | — | — | — |
| Joint Pain Management Therapies | — | — | — | — | — | — | $103,466,000 | $96,719,000 |
| Joint Preservation and Restoration | — | — | — | — | $48,588,000 | $39,368,000 | $2,070,000 | $1,127,000 |
| Licensing Milestone and Contract Revenue | — | — | — | — | — | — | $98,000 | — |
| Nonorthopedic | — | — | — | — | $14,122,000 | $8,060,000 | $8,976,000 | — |
| OA Pain Management | — | — | — | — | $85,084,000 | $83,029,000 | $103,466,000 | — |
| Manufactured Product Other | — | — | — | — | — | — | $8,976,000 | $7,685,000 |
| Product | — | — | — | — | — | — | $114,512,000 | $105,531,000 |
| Service | — | — | — | — | — | — | $98,000 | $24,000 |
Key facts
CIK
898437
CUSIP
035255108
13F (30d)
11 filings
11 filers
Visit website
Investor relations